biological models early enough in a project’s lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.

With their new services-based business model, we are well-enabled to respond to the demands and challenges faced by the drug discovery industry. Their dedicated team of expert neurobiologists and extensive pharmaceutical industry experience, position us well as a preferred partner Over the past year they have collaborated with several large Pharma partners.